

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

Application Number	10/591,732
Filing Date	September 1, 2006
First Named Inventor	Dake et al.
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	13720-105071US2

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		4,816,568	03-28-1969	Hamilton, Jr., et al.	
		5,512,547	04-30-1996	Johnson, et al.	
		5,607,691	03-04-1997	Hale, et al.	
		5,629,030	05-13-1997	Leone-Bay, et al.	
		5,709,861	01-20-1998	Santiago, et al.	
		5,744,166	04-28-1998	Illium	
		5,747,641	05-05-1998	Frankel, et al.	
		5,756,468	05-26-1998	Johnson, et al.	
		5,766,605	06-16-1998	Sanders, et al.	
		5,795,587	08-18-1998	Gao, et al.	
		5,804,604	09-08-1998	Frankel, et al.	
		6,306,423	10-23-2001	Donovan, et al.	
		6,312,708	11-06-2001	Donovan	
		6,383,509	05-07-2002	Donovan, et al.	
		6,413,941	07-02-2002	Garrett, et al.	
		6,485,663	12-17-2002	Rothbard, et al.	
		6,506,399	01-14-2003	Donovan	
		6,585,993	07-01-2003	Donovan, et al.	
		6,593,292	07-15-2003	Rothbard, et al.	
		6,610,820	08-26-2003	Bonny	
		6,645,501	11-11-2003	Dowdy	
		6,669,951	12-30-2003	Rothbard, et al.	
		6,680,301	01-20-2004	Berg et al.	
		6,683,049	01-27-2004	Aoki, et al.	
		6,692,911	02-17-2004	Pack, et al.	
		6,730,293	05-04-2004	Rothbard, et al.	
		6,759,387	07-06-2004	Rothbard, et al.	
		6,831,059	12-14-2004	Donovan	
		6,866,856	03-15-2005	Lu, et al.	
		6,896,886	05-24-2005	Aoki, et al.	
		6,974,578	12-13-2005	Aoki, et al.	
		2002/0009491	01-24-2002	Rothbard, et al.	
		2002/0006905	01-17-2002	Aoki, et al.	
		2002/0086036	07-04-2002	Walker	
		2002/0107199	08-06-2002	Walker	
		2002/0127247	09-12-2002	Steward, et al.	
		2002/0131965	09-19-2002	Rothbard, et al.	
		2003/0022831	01-30-2003	Rothbard, et al.	
		2003/0032593	02-13-2003	Wender, et al.	
		2003/0027752	02-06-2003	Steward, et al.	

Examiner
SignatureDate
Considered

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 4

Complete If Known

Application Number	10/591,732
Filing Date	September 1, 2006
First Named Inventor	Dake et al.
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	13720-105071US2

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.†	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		20030113749	06-19-2003	Coleman	
		20030157134	08-21-2003	Aoki, et al.	
		20030219462	11-27-2003	Steward, et al.	
		2003/0083256	05-01-2003	Rothbard, et al.	
		20030162719	08-28-2003	Rothbard, et al.	
		2003/0185788	10-02-2003	Rothbard, et al.	
		2003/0138437	07-24-2003	Hunt	
		2003/0220480	11-27-2003	Bonny	
		2004/0009180	01-15-2004	Donovan	
		2004/0013687	01-22-2004	Simpson	
		2004/0013692	01-22-2004	Aoki, et al.	
		2004/0161405	08-19-2004	Rothbard, et al.	
		2004/0186045	09-23-2004	Rothbard, et al.	
		2004/0033241	02-19-2004	Donovan	
		2004/0127556	07-01-2004	Lu, et al.	
		2004/0192754	09-30-2004	Shapira, et al.	
		2004/0220386	11-04-2004	Steward, et al.	
		2004/0247623	12-09-2004	Cady	
		2004/0037853	02-26-2004	Borodic	
		2004/0147443	07-29-2004	Renauff	
		2004/0247614	12-09-2004	Dorr, et al.	
		2005/0074461	04-07-2005	Donovan	
		2005/0112146	05-26-2005	Graham	
		2005/0175636	08-11-2005	Donovan	
		2005/0232966	10-20-2005	Hughes	
		2005/0238667	10-27-2005	Hunt	
		2006/0018931	01-26-2006	Taylor	
		2006/0024331	02-02-2006	Fernandez-Salazar, et al.	
		2006/0040882	02-23-2006	Chen	
		2005/0232966	10-20-2005	Hughes	
		2005/0238667	10-27-2005	Hunt	
		2006/0018931	01-26-2006	Taylor	
		2006/0024331	02-02-2006	Fernandez-Salazar, et al.	
		2006/0040882	02-23-2006	Chen	

Examiner
Signature

Date
Considered

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3

of

1

Attorney Docket

Complete if Known

Application Number

10/591.732

Filing Date

September 1, 2006

First Named Inventor

Dake et al.

Art Unit

TBA

Examiner Name _____

TBA

Attorney Docket Number

13720-105071US2

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†6
		Country Code* - Number* - Kind Code* (if known)				
		EP 0737074	10-16-2006	Allergan		
		EP 1005867	06-07-2000	Allergan		
		EP 1185291	03-13-2002	BIOTECON GES FUER BIOTECHNOLOG		
		EP 1421948	05-26-2004	Allergan		
		EP 1477183	11-17-2004	Allergan		
		EP 1180524	02-20-2002	Lipotec, SA		
		WO 1992/07871	05-14-1992	Allelix Biopharma		
		WO 1994/04686	03-03-1994	Biogen Inc		
		WO 1987/40854	11-06-1987	Antivirals Inc		
		WO 2000/34308	6-15-2000	Univ Washington		
		WO 2001/13967	03-01-2001	Celigate		
		WO 2001/62297	08-30-2001	Celigate		
		WO 2002/069930	09-12-2002	Celigate		
		WO 2002/069986	08-29-2002	Celigate		
		WO 2002/067917	09-06-2002	Celigate		
		WO 2003/49772	06-19-2003	Celigate		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant. * Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is a fee (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

4

of

4

Complete if Known

Application Number	10/591,732
Filing Date	September 1, 2006
First Named Inventor	Dake et al.
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	13720-105071US2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		"AIDS. Use of HIV-1 TAT, to target and/or activate antigen-presenting cells, and/or to deliver cargo molecules" from http://pharmalicensing.com/public/outlicensing/view/3766 (2001)	
		Green, M. "Mutational analysis of HIV-1 TAT minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression", Cell, 58:215-223	
		Blanes-Mira et al., "Identification of SNARE Complex Modulators that inhibit Exocytosis from an Alpha-Helix-Constrained Combinatorial Library," Biochem. J., vol. 375, no. 1, pp. 159-166, October 1, 2003	
		Blanes-Mira et al., "Small Peptides Patterned After the N-Terminus Domain of SNAP25 Inhibit SNARE Complex Assembly and Regulated Exocytosis," J. of Neurochem., vol. 88, no. 1, pp. 124-135, January 2004	
		Blanes-Mira et al., "A Synthetic Hexapeptide (Argireline) with Antiwrinkle Activity," Int'l J. of Cosmetic Science, vol. 24, no. 5, pp. 303-310, 2002	
		Fisher et al., "Matrix Sialoprotein of Developing Bone," J. Biol. Chem., vol. 268, pp. 12723-12727, October 1993	
		http://www.genlantis.com/catalog/product_line.cfm?product_family_key=13&product_line_key=54 , retrieved from the internet on 9/2/2005	
		Ambache, N. "A further survey of the action of clostridium botulinum toxin upon different types of autonomic nerve fibre" J. Physiol. (1951), 113, 1-17	
		Glogau, R., "Botulinum toxin A neurotoxin for axillary hyperhidrosis - no sweat Botox", Dermatol surg. 1998 Aug. 24(8) 817-819	
		Bermann I, et al. "Selective degeneration of sudomotor fibers in Ross Syndrome and successful treatment of compensatory hyperhidrosis with botulinum toxin", Muscle & Nerve 21(12):1790-1793	
		Hackman, M. Et al. "Botulinum toxin for axillary hyperhidrosis (excessive sweating)", N. Engl. J. Med. 344(7): 488-493	
		Lim, E. et al. "Topical botulinum toxin to treat hyperhidrosis? No sweat!" Medical Hypotheses, Volume 67, Issue 1, Pages 27-32	
		Nauman, M. et al. "Focal Hyperhidrosis - Effective Treatment with Intracutaneous Botulinum Toxin", Arch Dermatol. 134, 301-304	
		Naver H., "The treatment of focal hyperhidrosis with botulinum toxin", Eur J Neurol 1997; 4(Suppl 2):S75-9	
		Odderson, L., "Axillary hyperhidrosis: Treatment with Botulinum Toxin A", Arch Phys Med Rehabil 79(3):350-2	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to be paid by the USPTO to process an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1460, Alexandria, VA 22313-1460. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1460, Alexandria, VA 22313-1460. If you need assistance in completing the form, call 1-800-PTO-6199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

RELATED CASE STATEMENT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/591,732
Filing Date	September 1, 2006
First Named Inventor	Dake et al.
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	13720-105071US2

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number	Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
		Number - Kind Code ² (if known)			
	1	20070077259	03-03-2006	Dake, et al.	
	2	20030229034	07-20-2001	Waugh, et al.	
	3	20040220100	11-04-2004	Waugh, et al.	
	4	20050239705	03-03-2005	Dake et al.	
	6	20050196414	03-03-2005	Dake et al.	
	7	11/816,602	08-17-2007	Dake, et al.	
	8	10/591,486	06-18-2007	Dake, et al.	
	9	10/591,485	09-01-2006	Waugh et al.	
	10	11/955,076	12-12-2007	Waugh, et al.	
	11	11/954,885	12-12-2007	Waugh et al.	

Examiner
SignatureDate
Considered